Pacira BioSciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Pacira BioSciences (NASDAQ: PCRX) announced on October 3, 2025 that it granted inducement equity awards on October 2, 2025 to 15 new employees under its Amended and Restated 2014 Inducement Plan in accordance with Nasdaq Listing Rule 5635(c)(4).
Six employees received stock options for an aggregate of 18,000 shares (10-year term; exercise price $24.58; four-year vesting with 25% at one year). Fifteen employees received restricted stock units totaling 32,600 shares (vest annually in four equal installments beginning Oct 1, 2026). Vesting is subject to continued employment and award agreements.
Pacira BioSciences (NASDAQ: PCRX) ha annunciato il 3 ottobre 2025 che ha concesso premi azionari di induzione il 2 ottobre 2025 a 15 nuovi dipendenti ai sensi del suo Amended and Restated 2014 Inducement Plan come previsto dalla Nasdaq Listing Rule 5635(c)(4).
Sei dipendenti hanno ricevuto stock option per un totale di 18.000 azioni (termine di 10 anni; prezzo di esercizio $24,58; vesting di quattro anni con il 25% al secondo anno). Quindici dipendenti hanno ricevuto unità azionarie restrittive per un totale di 32.600 azioni (vesting annuale in quattro rate uguali a partire da 1 ottobre 2026). Il vesting è soggetto al continuo impiego e agli accordi di premi.
Pacira BioSciences (NASDAQ: PCRX) anunció el 3 de octubre de 2025 que concedió recompensas de acciones por inducción el 2 de octubre de 2025 a 15 nuevos empleados conforme a su Plan de Inducción de 2014, enmendado y reformulado, de acuerdo con la Regla de Listado Nasdaq 5635(c)(4).
Seis empleados recibieron opciones sobre acciones por un total de 18,000 acciones (plazo de 10 años; precio de ejercicio $24.58; consolidación de cuatro años con un 25% tras un año). Quince empleados recibieron unidades de acciones restringidas por un total de 32,600 acciones (con vesting anual en cuatro cuotas iguales a partir del 1 de octubre de 2026). El vesting está sujeto al empleo continuo y a los acuerdos de premios.
Pacira BioSciences (NASDAQ: PCRX)는 2025년 10월 3일에 2025년 10월 2일에 채용 보상 부여를 15명의 신규 직원에게 부여했고 이는 Nasdaq Listing Rule 5635(c)(4)에 따라 개정 및 재정의된 2014년 Inducement Plan에 따른 것이라고 발표했습니다.
6명의 직원은 총 18,000주에 대한 스톡 옵션(만료 기간 10년; 행사 가격 $24.58; 4년 vesting 중 1년 시점에 25% 부여). 15명의 직원은 총 32,600주의 제한 주식 유닛(RSU)을 받았으며(매년 4회 동일한 분할로 시작 2026년 10월 1일에 vesting). vesting은 지속 고용 및 수여 계약의 조건에 따릅니다.
Pacira BioSciences (NASDAQ: PCRX) a annoncé le 3 octobre 2025 qu'il a accordé des attributions d'actions d'induction le 2 octobre 2025 à 15 nouveaux employés dans le cadre de son Plan d'induction 2014 modifié et révisé, conformément à la Règle de cotation Nasdaq 5635(c)(4).
Six employés ont reçu des options d'achat d'actions pour un total de 18 000 actions (délai de 10 ans; prix d'exercice $24,58; vesting sur quatre ans avec 25 % à la fin de la première année). Quinze employés ont reçu des unités d'actions restreintes totalisant 32 600 actions (vesting annuel en quatre versements égaux à partir du 1er octobre 2026). Le vesting est soumis à l'emploi continu et aux accords de l'octroi.
Pacira BioSciences (NASDAQ: PCRX) gab am 3. Oktober 2025 bekannt, dass es am 2. Oktober 2025 Inducement-Eigenkapitalzuteilungen an 15 neue Mitarbeitende gemäß dem überarbeiteten Plan von 2014 Inducement Plan gemäß der Nasdaq Listing Rule 5635(c)(4) gewährt hat.
Sechs Mitarbeitende erhielten Aktienoptionen über insgesamt 18.000 Aktien (Laufzeit 10 Jahre; Ausübungspreis $24,58; Vesting vier Jahre, 25% nach einem Jahr). Fünfzehn Mitarbeitende erhielten Restricted Stock Units in Gesamthöhe von 32.600 Aktien (Vesting jährlich in vier gleichen Raten beginnend am 1. Oktober 2026). Das Vesting unterliegt der fortgesetzten Beschäftigung und den Award-Vereinbarungen.
Pacira BioSciences (NASDAQ: PCRX) أعلنت في 3 أكتوبر 2025 أنها منحت جوائز أسهم تشجيعية في 2 أكتوبر 2025 لـ 15 موظفاً جديداً بموجب خطتها 2014 المعدل والمفسر Inducement Plan وفقاً لـ قاعدة إدراج ناسداك 5635(c)(4).
حصل ستة موظفين على خيارات أسهم بإجمالي 18,000 سهماً (مدة عشر سنوات؛ سعر ممارسة $24.58; vesting لمدة أربع سنوات مع 25% في نهاية السنة الأولى). حصل خمسة عشر موظفاً على وحدات أسهم مقيدة بإجمالي 32,600 سهماً (يتم vesting سنوياً على مدى أربع دفعات متساوية بدءاً من 1 أكتوبر 2026). vesting مشروط باستمرار التوظيف وبالاتفاقيات الخاصة بالجوائز.
Pacira BioSciences (NASDAQ: PCRX)宣布于2025年10月3日向2025年10月2日根据其经修订并重新表述的2014年诱导计划，向15名新员工授予诱导性股票奖励，符合纳斯达克上市规则5635(c)(4)。
六名员工获得总额为18,000股的股票期权（期限10年；行权价$24.58；四年归属，首年归属25%）。十五名员工获得总计32,600股的受限股票单位（RSU），按四等份于2026年10月1日起每年等额归属。归属须持续雇佣及奖励协议之条件。
- None.
- None.
BRISBANE, Calif., Oct. 03, 2025 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in the delivery of innovative, non-opioid pain therapies to transform the lives of patients, today announced the granting of inducement awards on October 2, 2025 to 15 new employees under Pacira’s Amended and Restated 2014 Inducement Plan (the “Inducement Plan”) as a material inducement to each employee’s entry into employment with the company. In accordance with Nasdaq Listing Rule 5635(c)(4), the awards were approved by the People & Compensation Committee of the Board of Directors (the “Committee”) without stockholder approval.
Six employees received stock options to purchase an aggregate of 18,000 shares of Pacira common stock and 15 employees received restricted stock units for an aggregate of 32,600 shares of Pacira common stock. The stock options have a 10-year term and a four-year vesting schedule with 25 percent of the underlying shares vesting on the first anniversary of the recipient’s first day of employment and in successive equal quarterly installments over the 36 months thereafter. The stock options have an exercise price of
Vesting of the equity awards is subject to the employee’s continued employment with Pacira. Each equity award is also subject to the terms and conditions of an award agreement.
About Pacira
Pacira delivers innovative, non-opioid pain therapies to transform the lives of patients. Pacira has three commercial-stage non-opioid treatments: EXPAREL® (bupivacaine liposome injectable suspension), a long-acting local analgesic currently approved for infiltration, fascial plane block, and as an interscalene brachial plexus nerve block, an adductor canal nerve block, and a sciatic nerve block in the popliteal fossa for postsurgical pain management; ZILRETTA® (triamcinolone acetonide extended-release injectable suspension), an extended-release, intra-articular injection indicated for the management of osteoarthritis knee pain; and iovera®º, a novel, handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve. The Company is also advancing the development of PCRX-201 (enekinragene inzadenovec), a novel, locally administered gene therapy with the potential to treat large prevalent diseases like osteoarthritis. To learn more about Pacira, visit www.pacira.com.
| Investor Contact: Susan Mesco, (973) 451-4030 susan.mesco@pacira.com | Media Contact: Sara Marino, (973) 370-5430 sara.marino@pacira.com |
FAQ
What inducement awards did Pacira (PCRX) grant on October 2, 2025?
What are the terms of the Pacira (PCRX) stock options granted October 2, 2025?
When do the restricted stock units (RSUs) granted by Pacira (PCRX) begin vesting?
Why did Pacira (PCRX) use Nasdaq Listing Rule 5635(c)(4) for these grants?
How many employees received awards in Pacira's October 2, 2025 inducement grants?
What conditions govern vesting for the Pacira (PCRX) inducement awards?
